Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001104659-23-028602)

Filing Details

Accession Number:
0001104659-23-028602
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-03 20:00:45
Reporting Period:
2023-02-27
Accepted Time:
2023-03-03 20:00:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1651407 Checkpoint Therapeutics Inc. CKPT Pharmaceutical Preparations (2834) 472568632
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1692961 Garrett William Gray 95 Sawyer Rd, Suite 110
Waltham MA 02453		 Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-27 1,914 $4.66 47,465 No 4 S Direct
Common Stock Acquisiton 2023-02-27 7,500 $0.00 54,965 No 4 A Direct
Common Stock Disposition 2023-03-02 3,591 $5.00 51,374 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
No 4 S Direct
Footnotes
  1. In connection with the vesting of 3,925 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Gray's tax withholding obligations. Mr. Gray had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
  2. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $4.65 to $4.69. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Includes shares of restricted common stock, which vest over various time periods.
  4. Represents previously-granted performance-based award that became vested upon achievement of a corporate milestone on February 27, 2023.
  5. In connection with the vesting of 7,500 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Gray's tax withholding obligations. Mr. Gray had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
  6. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $5.00 to $5.025. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.